Data Insights

NX-5948 by Nurix Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Mantle Cell Lymphoma

Data Insights

NX-5948 by Nurix Therapeutics for Follicular Lymphoma: Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Follicular Lymphoma

Data Insights

NX-5948 by Nurix Therapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

NX-5948 by Nurix Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Marginal Zone B-cell Lymphoma

Data Insights

NX-5948 by Nurix Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Diffuse Large B-Cell Lymphoma

Data Insights

NX-5948 by Nurix Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

NX-5948 by Nurix Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL)